782 related articles for article (PubMed ID: 32699581)
1. Sorafenib combined with embolization plus hepatic arterial infusion chemotherapy for inoperable hepatocellular carcinoma.
Liu BJ; Gao S; Zhu X; Guo JH; Zhang X; Chen H; Wang XD; Yang RJ
World J Gastrointest Oncol; 2020 Jun; 12(6):663-676. PubMed ID: 32699581
[TBL] [Abstract][Full Text] [Related]
2. Transarterial chemoembolization with hepatic arterial infusion chemotherapy plus S-1 for hepatocellular carcinoma.
Guo JH; Liu SX; Gao S; Kou FX; Zhang X; Wu D; Li XT; Chen H; Wang XD; Liu P; Zhang PJ; Xu HF; Cao G; Zhu LZ; Yang RJ; Zhu X
World J Gastroenterol; 2020 Jul; 26(27):3975-3988. PubMed ID: 32774071
[TBL] [Abstract][Full Text] [Related]
3. Hepatic artery infusion chemotherapy using mFOLFOX versus transarterial chemoembolization for massive unresectable hepatocellular carcinoma: a prospective non-randomized study.
He MK; Le Y; Li QJ; Yu ZS; Li SH; Wei W; Guo RP; Shi M
Chin J Cancer; 2017 Oct; 36(1):83. PubMed ID: 29061175
[TBL] [Abstract][Full Text] [Related]
4. Safety and efficacy of hepatic arterial infusion chemotherapy with raltitrexed and oxaliplatin post-transarterial chemoembolization for unresectable hepatocellular carcinoma.
Liu B; Zhu X; Gao S; Guo J; Wang X; Cao G; Zhu L; Liu P; Xu H; Chen H; Zhang X; Liu S; Kou F
J Interv Med; 2019 May; 2(2):91-96. PubMed ID: 34805879
[TBL] [Abstract][Full Text] [Related]
5. Hepatic Arterial Infusion Chemotherapy Using Oxaliplatin Plus 5-Fluorouracil Versus Transarterial Chemoembolization/Embolization for the Treatment of Advanced Hepatocellular Carcinoma with Major Portal Vein Tumor Thrombosis.
Hu J; Bao Q; Cao G; Zhu X; Yang R; Ji X; Xu L; Zheng K; Li W; Xing B; Wang X
Cardiovasc Intervent Radiol; 2020 Jul; 43(7):996-1005. PubMed ID: 31974744
[TBL] [Abstract][Full Text] [Related]
6. Tyrosine kinase inhibitors, immune checkpoint inhibitors combined with hepatic arterial infusion of oxaliplatin and raltitrexed versus oxaliplatin, 5-fluorouracil and leucovorin for intermediate and advanced hepatocellular carcinoma: A retrospective study.
Zang M; Hu X; Yuan G; Li R; Li W; Pang H; Li Q; Chen J
Int Immunopharmacol; 2023 Dec; 125(Pt A):111019. PubMed ID: 37879230
[TBL] [Abstract][Full Text] [Related]
7. Chemoembolization alone vs combined chemoembolization and hepatic arterial infusion chemotherapy in inoperable hepatocellular carcinoma patients.
Gao S; Zhang PJ; Guo JH; Chen H; Xu HF; Liu P; Yang RJ; Zhu X
World J Gastroenterol; 2015 Sep; 21(36):10443-52. PubMed ID: 26420971
[TBL] [Abstract][Full Text] [Related]
8. Intermediate-advanced hepatocellular carcinoma in Argentina: Treatment and survival analysis.
Piñero F; Marciano S; Fernández N; Silva J; Anders M; Zerega A; Ridruejo E; Romero G; Ameigeiras B; D'Amico C; Gaite L; Bermúdez C; Reggiardo V; Colombato L; Gadano A; Silva M
World J Gastroenterol; 2019 Jul; 25(27):3607-3618. PubMed ID: 31367160
[TBL] [Abstract][Full Text] [Related]
9. Hepatic Arterial Infusion Chemotherapy with Modified FOLFOX as an Alternative Treatment Option in Advanced Hepatocellular Carcinoma Patients with Failed or Unsuitability for Transarterial Chemoembolization.
Hsu SJ; Xu X; Chen MP; Zhao ZY; Wang Y; Yin X; Zhang L; Ge NL; Chen Y; Wang YH; Luo JF; Ren ZG; Chen RX
Acad Radiol; 2021 Nov; 28 Suppl 1():S157-S166. PubMed ID: 33653656
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of hepatic arterial infusion chemotherapy combined with transarterial embolization for unresectable hepatocellular carcinoma: A propensity score-matching cohort study.
Guo W; Gao J; Zhuang W; Wu Z; Li B; Chen S
JGH Open; 2020 Jun; 4(3):477-483. PubMed ID: 32514457
[TBL] [Abstract][Full Text] [Related]
11. Effect and safety of sorafenib in patients with intermediate hepatocellular carcinoma who received transarterial chemoembolization: A retrospective comparative study.
Lei XF; Ke Y; Bao TH; Tang HR; Wu XS; Shi ZT; Lin J; Zhang ZX; Gu H; Wang L
World J Clin Cases; 2018 May; 6(5):74-83. PubMed ID: 29774219
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and Safety of HepaSphere Drug-Eluting Bead Transarterial Chemoembolization Combined with Hepatic Arterial Infusion Chemotherapy as the Second-Line Treatment in Advanced Hepatocellular Carcinoma.
Liu B; Gao S; Guo J; Kou F; Liu S; Zhang X; Feng A; Wang X; Cao G; Chen H; Liu P; Xu H; Gao Q; Yang R; Xu L; Zhu X
J Hepatocell Carcinoma; 2024; 11():477-488. PubMed ID: 38463543
[TBL] [Abstract][Full Text] [Related]
13. Comparison of clinical outcome of hepatic arterial infusion chemotherapy and sorafenib for advanced hepatocellular carcinoma according to macrovascular invasion and transcatheter arterial chemoembolization refractory status.
Kodama K; Kawaoka T; Aikata H; Uchikawa S; Inagaki Y; Hatooka M; Morio K; Nakahara T; Murakami E; Tsuge M; Hiramatsu A; Imamura M; Kawakami Y; Masaki K; Honda Y; Mori N; Takaki S; Tsuji K; Kohno H; Kohno H; Moriya T; Nonaka M; Hyogo H; Aisaka Y; Chayama K
J Gastroenterol Hepatol; 2018 Oct; 33(10):1780-1786. PubMed ID: 29645345
[TBL] [Abstract][Full Text] [Related]
14. Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin Versus Sorafenib for Hepatocellular Carcinoma Refractory to Transarterial Chemoembolization: Retrospective Subgroup Analysis of 2 Prospective Trials.
Huang Y; Zhang L; He M; Lai Z; Bu X; Wen D; Li Q; Xu L; Wei W; Zhang Y; Zhou Z; Chen M; Guo R; Shi M; Kan A
Technol Cancer Res Treat; 2022; 21():15330338221117389. PubMed ID: 36529949
[No Abstract] [Full Text] [Related]
15. Phase II Study of Sorafenib Combined with Concurrent Hepatic Arterial Infusion of Oxaliplatin, 5-Fluorouracil and Leucovorin for Unresectable Hepatocellular Carcinoma with Major Portal Vein Thrombosis.
He MK; Zou RH; Li QJ; Zhou ZG; Shen JX; Zhang YF; Yu ZS; Xu L; Shi M
Cardiovasc Intervent Radiol; 2018 May; 41(5):734-743. PubMed ID: 29327075
[TBL] [Abstract][Full Text] [Related]
16. Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma.
Lyu N; Kong Y; Mu L; Lin Y; Li J; Liu Y; Zhang Z; Zheng L; Deng H; Li S; Xie Q; Guo R; Shi M; Xu L; Cai X; Wu P; Zhao M
J Hepatol; 2018 Jul; 69(1):60-69. PubMed ID: 29471013
[TBL] [Abstract][Full Text] [Related]
17. Sorafenib Plus Hepatic Arterial Infusion Chemotherapy versus Sorafenib for Hepatocellular Carcinoma with Major Portal Vein Tumor Thrombosis: A Randomized Trial.
Zheng K; Zhu X; Fu S; Cao G; Li WQ; Xu L; Chen H; Wu D; Yang R; Wang K; Liu W; Wang H; Bao Q; Liu M; Hao C; Shen L; Xing B; Wang X
Radiology; 2022 May; 303(2):455-464. PubMed ID: 35103539
[TBL] [Abstract][Full Text] [Related]
18. Comparison Between Portal Vein Perfusion Chemotherapy and Neoadjuvant Hepatic Arterial Infusion Chemotherapy for Resectable Intermediate to Advanced Stage Hepatocellular Carcinoma.
Pan Y; Mei J; Chen J; Zhang D; Wang J; Wang X; Yi M; Zhou Z; Zhang Y; Chen M; Guo R; Xu L
Ann Surg Oncol; 2022 Mar; 29(3):2016-2029. PubMed ID: 34637058
[TBL] [Abstract][Full Text] [Related]
19. Comparison of Outcome of Hepatic Arterial Infusion Chemotherapy and Sorafenib in Patients with Hepatocellular Carcinoma Refractory to Transcatheter Arterial Chemoembolization.
Hatooka M; Kawaoka T; Aikata H; Morio K; Kobayashi T; Hiramatsu A; Imamura M; Kawakami Y; Murakami E; Waki K; Honda Y; Mori N; Takaki S; Tsuji K; Kohno H; Kohno H; Moriya T; Nonaka M; Hyogo H; Aisaka Y; Chayama K
Anticancer Res; 2016 Jul; 36(7):3523-9. PubMed ID: 27354618
[TBL] [Abstract][Full Text] [Related]
20. The safety and efficacy of transarterial chemoembolization combined with sorafenib and sorafenib mono-therapy in patients with BCLC stage B/C hepatocellular carcinoma.
Wu FX; Chen J; Bai T; Zhu SL; Yang TB; Qi LN; Zou L; Li ZH; Ye JZ; Li LQ
BMC Cancer; 2017 Sep; 17(1):645. PubMed ID: 28899349
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
